\documentclass[11pt,twoside]{article}\makeatletter

\IfFileExists{xcolor.sty}%
  {\RequirePackage{xcolor}}%
  {\RequirePackage{color}}
\usepackage{colortbl}
\usepackage{wrapfig}
\usepackage{ifxetex}
\ifxetex
  \usepackage{fontspec}
  \usepackage{xunicode}
  \catcode`⃥=\active \def⃥{\textbackslash}
  \catcode`❴=\active \def❴{\{}
  \catcode`❵=\active \def❵{\}}
  \def\textJapanese{\fontspec{Noto Sans CJK JP}}
  \def\textChinese{\fontspec{Noto Sans CJK SC}}
  \def\textKorean{\fontspec{Noto Sans CJK KR}}
  \setmonofont{DejaVu Sans Mono}
  
\else
  \IfFileExists{utf8x.def}%
   {\usepackage[utf8x]{inputenc}
      \PrerenderUnicode{–}
    }%
   {\usepackage[utf8]{inputenc}}
  \usepackage[english]{babel}
  \usepackage[T1]{fontenc}
  \usepackage{float}
  \usepackage[]{ucs}
  \uc@dclc{8421}{default}{\textbackslash }
  \uc@dclc{10100}{default}{\{}
  \uc@dclc{10101}{default}{\}}
  \uc@dclc{8491}{default}{\AA{}}
  \uc@dclc{8239}{default}{\,}
  \uc@dclc{20154}{default}{ }
  \uc@dclc{10148}{default}{>}
  \def\textschwa{\rotatebox{-90}{e}}
  \def\textJapanese{}
  \def\textChinese{}
  \IfFileExists{tipa.sty}{\usepackage{tipa}}{}
\fi
\def\exampleFont{\ttfamily\small}
\DeclareTextSymbol{\textpi}{OML}{25}
\usepackage{relsize}
\RequirePackage{array}
\def\@testpach{\@chclass
 \ifnum \@lastchclass=6 \@ne \@chnum \@ne \else
  \ifnum \@lastchclass=7 5 \else
   \ifnum \@lastchclass=8 \tw@ \else
    \ifnum \@lastchclass=9 \thr@@
   \else \z@
   \ifnum \@lastchclass = 10 \else
   \edef\@nextchar{\expandafter\string\@nextchar}%
   \@chnum
   \if \@nextchar c\z@ \else
    \if \@nextchar l\@ne \else
     \if \@nextchar r\tw@ \else
   \z@ \@chclass
   \if\@nextchar |\@ne \else
    \if \@nextchar !6 \else
     \if \@nextchar @7 \else
      \if \@nextchar (8 \else
       \if \@nextchar )9 \else
  10
  \@chnum
  \if \@nextchar m\thr@@\else
   \if \@nextchar p4 \else
    \if \@nextchar b5 \else
   \z@ \@chclass \z@ \@preamerr \z@ \fi \fi \fi \fi
   \fi \fi  \fi  \fi  \fi  \fi  \fi \fi \fi \fi \fi \fi}
\gdef\arraybackslash{\let\\=\@arraycr}
\def\@textsubscript#1{{\m@th\ensuremath{_{\mbox{\fontsize\sf@size\z@#1}}}}}
\def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}}
\def\abbr{}
\def\corr{}
\def\expan{}
\def\gap{}
\def\orig{}
\def\reg{}
\def\ref{}
\def\sic{}
\def\persName{}\def\name{}
\def\placeName{}
\def\orgName{}
\def\textcal#1{{\fontspec{Lucida Calligraphy}#1}}
\def\textgothic#1{{\fontspec{Lucida Blackletter}#1}}
\def\textlarge#1{{\large #1}}
\def\textoverbar#1{\ensuremath{\overline{#1}}}
\def\textquoted#1{‘#1’}
\def\textsmall#1{{\small #1}}
\def\textsubscript#1{\@textsubscript{\selectfont#1}}
\def\textxi{\ensuremath{\xi}}
\def\titlem{\itshape}
\newenvironment{biblfree}{}{\ifvmode\par\fi }
\newenvironment{bibl}{}{}
\newenvironment{byline}{\vskip6pt\itshape\fontsize{16pt}{18pt}\selectfont}{\par }
\newenvironment{citbibl}{}{\ifvmode\par\fi }
\newenvironment{docAuthor}{\ifvmode\vskip4pt\fontsize{16pt}{18pt}\selectfont\fi\itshape}{\ifvmode\par\fi }
\newenvironment{docDate}{}{\ifvmode\par\fi }
\newenvironment{docImprint}{\vskip 6pt}{\ifvmode\par\fi }
\newenvironment{docTitle}{\vskip6pt\bfseries\fontsize{22pt}{25pt}\selectfont}{\par }
\newenvironment{msHead}{\vskip 6pt}{\par}
\newenvironment{msItem}{\vskip 6pt}{\par}
\newenvironment{rubric}{}{}
\newenvironment{titlePart}{}{\par }

\newcolumntype{L}[1]{){\raggedright\arraybackslash}p{#1}}
\newcolumntype{C}[1]{){\centering\arraybackslash}p{#1}}
\newcolumntype{R}[1]{){\raggedleft\arraybackslash}p{#1}}
\newcolumntype{P}[1]{){\arraybackslash}p{#1}}
\newcolumntype{B}[1]{){\arraybackslash}b{#1}}
\newcolumntype{M}[1]{){\arraybackslash}m{#1}}
\definecolor{label}{gray}{0.75}
\def\unusedattribute#1{\sout{\textcolor{label}{#1}}}
\DeclareRobustCommand*{\xref}{\hyper@normalise\xref@}
\def\xref@#1#2{\hyper@linkurl{#2}{#1}}
\begingroup
\catcode`\_=\active
\gdef_#1{\ensuremath{\sb{\mathrm{#1}}}}
\endgroup
\mathcode`\_=\string"8000
\catcode`\_=12\relax

\usepackage[a4paper,twoside,lmargin=1in,rmargin=1in,tmargin=1in,bmargin=1in,marginparwidth=0.75in]{geometry}
\usepackage{framed}

\definecolor{shadecolor}{gray}{0.95}
\usepackage{longtable}
\usepackage[normalem]{ulem}
\usepackage{fancyvrb}
\usepackage{fancyhdr}
\usepackage{graphicx}
\usepackage{marginnote}

\renewcommand{\@cite}[1]{#1}


\renewcommand*{\marginfont}{\itshape\footnotesize}

\def\Gin@extensions{.pdf,.png,.jpg,.mps,.tif}

  \pagestyle{fancy}

\usepackage[pdftitle={Collection, Detection, Assessment, Monitoring and Prevention of Adverse Drug Reactions in the},
 pdfauthor={}]{hyperref}
\hyperbaseurl{}

	 \paperwidth210mm
	 \paperheight297mm
              
\def\@pnumwidth{1.55em}
\def\@tocrmarg {2.55em}
\def\@dotsep{4.5}
\setcounter{tocdepth}{3}
\clubpenalty=8000
\emergencystretch 3em
\hbadness=4000
\hyphenpenalty=400
\pretolerance=750
\tolerance=2000
\vbadness=4000
\widowpenalty=10000

\renewcommand\section{\@startsection {section}{1}{\z@}%
     {-1.75ex \@plus -0.5ex \@minus -.2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\Large\bfseries}}
\renewcommand\subsection{\@startsection{subsection}{2}{\z@}%
     {-1.75ex\@plus -0.5ex \@minus- .2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\Large}}
\renewcommand\subsubsection{\@startsection{subsubsection}{3}{\z@}%
     {-1.5ex\@plus -0.35ex \@minus -.2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\large}}
\renewcommand\paragraph{\@startsection{paragraph}{4}{\z@}%
     {-1ex \@plus-0.35ex \@minus -0.2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\normalsize}}
\renewcommand\subparagraph{\@startsection{subparagraph}{5}{\parindent}%
     {1.5ex \@plus1ex \@minus .2ex}%
     {-1em}%
     {\reset@font\normalsize\bfseries}}


\def\l@section#1#2{\addpenalty{\@secpenalty} \addvspace{1.0em plus 1pt}
 \@tempdima 1.5em \begingroup
 \parindent \z@ \rightskip \@pnumwidth 
 \parfillskip -\@pnumwidth 
 \bfseries \leavevmode #1\hfil \hbox to\@pnumwidth{\hss #2}\par
 \endgroup}
\def\l@subsection{\@dottedtocline{2}{1.5em}{2.3em}}
\def\l@subsubsection{\@dottedtocline{3}{3.8em}{3.2em}}
\def\l@paragraph{\@dottedtocline{4}{7.0em}{4.1em}}
\def\l@subparagraph{\@dottedtocline{5}{10em}{5em}}
\@ifundefined{c@section}{\newcounter{section}}{}
\@ifundefined{c@chapter}{\newcounter{chapter}}{}
\newif\if@mainmatter 
\@mainmattertrue
\def\chaptername{Chapter}
\def\frontmatter{%
  \pagenumbering{roman}
  \def\thechapter{\@roman\c@chapter}
  \def\theHchapter{\roman{chapter}}
  \def\thesection{\@roman\c@section}
  \def\theHsection{\roman{section}}
  \def\@chapapp{}%
}
\def\mainmatter{%
  \cleardoublepage
  \def\thechapter{\@arabic\c@chapter}
  \setcounter{chapter}{0}
  \setcounter{section}{0}
  \pagenumbering{arabic}
  \setcounter{secnumdepth}{6}
  \def\@chapapp{\chaptername}%
  \def\theHchapter{\arabic{chapter}}
  \def\thesection{\@arabic\c@section}
  \def\theHsection{\arabic{section}}
}
\def\backmatter{%
  \cleardoublepage
  \setcounter{chapter}{0}
  \setcounter{section}{0}
  \setcounter{secnumdepth}{2}
  \def\@chapapp{\appendixname}%
  \def\thechapter{\@Alph\c@chapter}
  \def\theHchapter{\Alph{chapter}}
  \appendix
}
\newenvironment{bibitemlist}[1]{%
   \list{\@biblabel{\@arabic\c@enumiv}}%
       {\settowidth\labelwidth{\@biblabel{#1}}%
        \leftmargin\labelwidth
        \advance\leftmargin\labelsep
        \@openbib@code
        \usecounter{enumiv}%
        \let\p@enumiv\@empty
        \renewcommand\theenumiv{\@arabic\c@enumiv}%
	}%
  \sloppy
  \clubpenalty4000
  \@clubpenalty \clubpenalty
  \widowpenalty4000%
  \sfcode`\.\@m}%
  {\def\@noitemerr
    {\@latex@warning{Empty `bibitemlist' environment}}%
    \endlist}

\def\tableofcontents{\section*{\contentsname}\@starttoc{toc}}
\parskip0pt
\parindent1em
\def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}}
\newenvironment{reflist}{%
  \begin{raggedright}\begin{list}{}
  {%
   \setlength{\topsep}{0pt}%
   \setlength{\rightmargin}{0.25in}%
   \setlength{\itemsep}{0pt}%
   \setlength{\itemindent}{0pt}%
   \setlength{\parskip}{0pt}%
   \setlength{\parsep}{2pt}%
   \def\makelabel##1{\itshape ##1}}%
  }
  {\end{list}\end{raggedright}}
\newenvironment{sansreflist}{%
  \begin{raggedright}\begin{list}{}
  {%
   \setlength{\topsep}{0pt}%
   \setlength{\rightmargin}{0.25in}%
   \setlength{\itemindent}{0pt}%
   \setlength{\parskip}{0pt}%
   \setlength{\itemsep}{0pt}%
   \setlength{\parsep}{2pt}%
   \def\makelabel##1{\upshape ##1}}%
  }
  {\end{list}\end{raggedright}}
\newenvironment{specHead}[2]%
 {\vspace{20pt}\hrule\vspace{10pt}%
  \phantomsection\label{#1}\markright{#2}%

  \pdfbookmark[2]{#2}{#1}%
  \hspace{-0.75in}{\bfseries\fontsize{16pt}{18pt}\selectfont#2}%
  }{}
      \def\TheFullDate{2014-01-15 (revised: 15 January 2014)}
\def\TheID{\makeatother }
\def\TheDate{2014-01-15}
\title{Collection, Detection, Assessment, Monitoring and Prevention of Adverse Drug Reactions in the}
\author{}\makeatletter 
\makeatletter
\newcommand*{\cleartoleftpage}{%
  \clearpage
    \if@twoside
    \ifodd\c@page
      \hbox{}\newpage
      \if@twocolumn
        \hbox{}\newpage
      \fi
    \fi
  \fi
}
\makeatother
\makeatletter
\thispagestyle{empty}
\markright{\@title}\markboth{\@title}{\@author}
\renewcommand\small{\@setfontsize\small{9pt}{11pt}\abovedisplayskip 8.5\p@ plus3\p@ minus4\p@
\belowdisplayskip \abovedisplayskip
\abovedisplayshortskip \z@ plus2\p@
\belowdisplayshortskip 4\p@ plus2\p@ minus2\p@
\def\@listi{\leftmargin\leftmargini
               \topsep 2\p@ plus1\p@ minus1\p@
               \parsep 2\p@ plus\p@ minus\p@
               \itemsep 1pt}
}
\makeatother
\fvset{frame=single,numberblanklines=false,xleftmargin=5mm,xrightmargin=5mm}
\fancyhf{} 
\setlength{\headheight}{14pt}
\fancyhead[LE]{\bfseries\leftmark} 
\fancyhead[RO]{\bfseries\rightmark} 
\fancyfoot[RO]{}
\fancyfoot[CO]{\thepage}
\fancyfoot[LO]{\TheID}
\fancyfoot[LE]{}
\fancyfoot[CE]{\thepage}
\fancyfoot[RE]{\TheID}
\hypersetup{citebordercolor=0.75 0.75 0.75,linkbordercolor=0.75 0.75 0.75,urlbordercolor=0.75 0.75 0.75,bookmarksnumbered=true}
\fancypagestyle{plain}{\fancyhead{}\renewcommand{\headrulewidth}{0pt}}

\date{}
\usepackage{authblk}

\providecommand{\keywords}[1]
{
\footnotesize
  \textbf{\textit{Index terms---}} #1
}

\usepackage{graphicx,xcolor}
\definecolor{GJBlue}{HTML}{273B81}
\definecolor{GJLightBlue}{HTML}{0A9DD9}
\definecolor{GJMediumGrey}{HTML}{6D6E70}
\definecolor{GJLightGrey}{HTML}{929497} 

\renewenvironment{abstract}{%
   \setlength{\parindent}{0pt}\raggedright
   \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}}
   \vskip16pt
   \textcolor{GJBlue}{\large\bfseries\abstractname\space}
}{%   
   \vskip8pt
   \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}}
   \vskip16pt
}

\usepackage[absolute,overlay]{textpos}

\makeatother 
      \usepackage{lineno}
      \linenumbers
      
\begin{document}

             \author[1]{Ramaiah  Maddi}

             \affil[1]{  HCOP}

\renewcommand\Authands{ and }

\date{\small \em Received: 9 December 2013 Accepted: 3 January 2014 Published: 15 January 2014}

\maketitle


\begin{abstract}
        


An adverse drug reaction (ADR) as defined by World Health Organization (WHO) is a noxious, unintended effect of a drug, occurring at normal doses in humans for prophylaxis, diagnosis or therapy of disease or for the modification of physiological function. ADRs are considered as the fourth to sixth leading cause of death among hospitalized patients. About 2.9-5.6% of all admissions are caused by adverse related events, and approximately 35% hospitalized patients experience an ADR.Objective: To identify the ADR by chart review method, to determine the causality of the ADR by Naranjo's algorithm, to analyze the severity of the ADR by modified Hartwig method and to motivate the health care professionals to report ADRs in Nephrology ward of Gauhatu Medical College and Hospital (GMCH), Guwahati. Preventability of ADR is done by Schumock &Thortonpreventibility scale. Materials and methods: A prospective observational and hospital based case control study(June 2011-May 2012)was carried out in the Nephrology ward of GHMC, including both out-patient and in-patient departments. All the values are statistically determined using parametric t-test and non-parametric fisher's exact test or chi-square tests.

\end{abstract}


\keywords{nephrology, renal dysfunction, moon face, hypersensitivity, hepatotoxicity.}

\begin{textblock*}{18cm}(1cm,1cm) % {block width} (coords) 
\textcolor{GJBlue}{\LARGE Global Journals \LaTeX\ JournalKaleidoscope\texttrademark}
\end{textblock*}

\begin{textblock*}{18cm}(1.4cm,1.5cm) % {block width} (coords) 
\textcolor{GJBlue}{\footnotesize \\ Artificial Intelligence formulated this projection for compatibility purposes from the original article published at Global Journals. However, this technology is currently in beta. \emph{Therefore, kindly ignore odd layouts, missed formulae, text, tables, or figures.}}
\end{textblock*}


\let\tabcellsep& 	 	 		 
\section[{Introduction}]{Introduction}\par
n adverse drug reaction (ADR) as defined by World Health Organization (WHO) is a noxious, unintended effect of a drug, occurring at normal doses in humans for prophylaxis, diagnosis or therapy of disease or for the modification of physiological function \hyperref[b0]{(1)}. ADRs are considered as the fourth to sixth leading cause of death among hospitalized patients. About 2.9-5.6\% of all admissions are caused by adverse related events, and approximately 35\% hospitalized patients experience an ADR. ADRs are associated with significant morbidity, permanent disability and are a huge economic burden on patients due to prolonged hospitalization \hyperref[b1]{(2)}.\par
Kidney is the primary route of elimination for drugs and their metabolites. Hydrophilic drugs are mainly cleared by the kidney \hyperref[b5]{(3)}. ADRs are most commonly observed in elderly patients \hyperref[b6]{(4)}. Aging is associated with decreased renal and liver reserve and with the risk of delayed renal and hepatic clearance of drugs. Renal function can be readily estimated by the serum creatinine level \hyperref[b5]{(3)}.\par
The Gauhati Medical College and hospital (GMCH) has enjoyed a prestigious status in the country for its academic pursuites and patients care, and thereby being a referral centre for speciality and superspeciality treatment having a bed strength of 1,587 and 17 operation theaters It provide promotive, preventive and curative, through out-patient department (OPD), indoor, emergency and extension Services. An ADR reporting program exists in the hospital since 1970 and the same was coordinated by the department of pharmacy practice, National Institute of Pharmaceutical Education and Research (NIPER), Gauhati. The present study was undertaken to characterize the ADRs reported in Nephrology department \hyperref[b7]{(5)}. 
\section[{II.}]{II.} 
\section[{Materials and Methods}]{Materials and Methods}\par
The study was carried out in the Nephrology ward of GHMC from June 2010 to May 2011 including both out-patient (OP) and in-patient (IP) departments.\par
The study was a prospective observational, hospital based case control study.It was based only on those patients who experience an adverse reaction to medicine use, either during their stay in hospital or outside the hospital and visiting the outpatient and inpatient departments of Nephrology.\par
The degree of association of an adverse effect with a drug is done (table \hyperref[tab_2]{1})with the help of Naranjo's algorithm where it involves a number of questionnaires, to each of which score has been provided (ranging from -1 to +2). Total score for a particular drug-ADR combination is calculated and the association is termed as>9: Highly probable; 5-8: Probable; 1-4: Possible; 0: Doubtful \hyperref[b8]{(6)}.\par
After the causality assessment has been done, the severity of the ADR is analyzed using adapted Hart wig severity scale \hyperref[b9]{(7)}.The scale was classified as mild:a reaction that does not required treatment or prolongation of hospital stay; moderate: a reaction that requires treatment and or prolongs hospitalization by at least one day; severe: a reaction that was potentially life threatening or contributes to the death of patient was permanently disabling requires intensive medical care or results in a congenital anomaly cancer or unintentional overdose.\par
Preventability of ADR is done by Schumock \& Thorton preventibility scale. Preventable adverse drug reaction was defined according to \hyperref[b10]{Schumock and Thornton (1992)} as ADR which was preventable or avoidable. There were seven questions. Answering "YES" to one or more of the questions that an ADR was preventable \hyperref[b10]{(8)}.\par
To study the onset of ADR, acute: those which are observed within 60 minutes after the administration of medication; sub-acute: those occur within 1-24 hours from the time of administration of medication; and latent: those take 2 or more days to become apparent, parameters were used. 
\section[{III.}]{III.} 
\section[{Statistical Analysis}]{Statistical Analysis}\par
Data were recorded on a pre-designed proforma and managed on an MS Office Excel spread sheet. The descriptive statistics are represented by mean ± standard deviation and percentages. The differences between the groups were determined by the parametric t-test and non-parametric fisher's exact test or chi-square tests wherever appropriate. Graph Pad InStat version 3.12 statistical software was used for the data analysis. The Odds ratio and its 95\% confidence interval were calculated for certain risk factor of ADRs in renal failure patients. Statistical significance was defined as p<0.05. All P values were two tailed.\par
IV. 
\section[{Results}]{Results}\par
The results were based on 850 patient records taken from the Nephrology department of GHMC. Out of them 72 (8.47\%) patients resulted in one or more ADRs. Thecommonly occurring ADRs were moon face (n=16, 18.6\%) followed by hypersensitivity (n=9, 10.4\%) and hepatotoxicity (n=4, 4.65\%)(Table2).\par
V. 
\section[{Types of Adrs by System}]{Types of Adrs by System}\par
Gastrointestinal ADRs were highest in number followed by the hypersensitivity ADRs. Gastrointestinal ADRs mainly include hepatotoxicity, ulcers, melaena, nausea, vomiting diarrhea and constipation (table \hyperref[tab_0]{2}). The causality assessment was done using Naranjo's scale and it shows that majority of the ADRs were probable (n= 87, 91.57\%). As the ADRs had been identified, their severity level was also assessed. This was done using Hartwig criteria and majority of the patients had mild ADR (n = 44, 51.16\%). Mostly ADRs have latent onset. It was very clear that 12.7\% ADRs were preventable.The other 87.2\% were not preventable because the susceptibility of these ADRs is still not defined and is a matter of research.This assessment is based on Schumoch and Thornton preventability criteria.In this study maximum number of ADRs found in one patient are 3.They are fluid electrolyte imbalance, blurred vision, hyperglycemia.\par
The incidence and certainty of ADRs in male and female were also studied. It was found that female populations showed a higher incidence of ADRs than in male populations (table \hyperref[tab_1]{3}).The percentage of ADRs was found out by dividing number of patients with ADRs of a particular gender by total number of patients of the same gender.\par
For gender, the p-value is 0.042 (<0.05). It shows that there is significant difference between occurrences of ADRs in different gender. In this study females were found to be more prone to ADR when compared to the male patients, similar to more other studies in the literature.\par
This study shows the incidence of ADRs with respect to age in which elderly patients(age >60) had a higher incidence of ADRs (15.00\%). The patients in between the age of 0-18 yrs were found to have 9.37\% and the age between 19-60 yrs had 7.98\%(table \hyperref[tab_1]{3}). For age, the p-value is 0.001(<0.05). It shows that there is significant difference between occurrences of ADRs in different age groups. In this study patients above 60 years were found to be more prone to ADR when compared to other age groups. OR -odds ratio, CI-confidence interval.\par
The prescription pattern in case of each patient with ADR was studied and accordingly the patients were divided into 3 groups namely, those receiving 1-5 numbers of drugs;those receiving 6-10 numbers of drugs; and those receiving more than 10 drugs. It was seen that patients receiving more number of drugs (>10)had higher chances of developing ADRs(9.45\%) (table3). A total of 450 medicines were prescribed in patients with adverse reactions. prednisolone was found to be the most offending drug followed by nimesulide and diclofenac (figure \hyperref[fig_0]{1}).  
\section[{Discussion}]{Discussion}\par
medicinal product beyond its intended therapeutic ADRs are the undesirable effects of the drug/ effect when used for clinical purposes. ADRs not only cause morbidity but also can be a reason for mortality in severe cases. They also contribute to greater extents in increasing health care costs to the patients and to the nation(9). This was a prospective observational study carried out in the Nephrology department of GMCH. Out of the total 850 patient records collected in the Nephrology ward, 72patients resulted in one or more ADRs. Similar studies done in other countries reported a higher rate of incidence(10\% to18\%) than this study.\par
The commonly occurring ADRs in this study were moon face followed by Allergic reactions. This study finding was in accordance with the results of several other studies in literature \hyperref[b1]{(2,}\hyperref[b6]{4,}\hyperref[b12]{10)}.Where moon face was found to be the common ADR associated with prednisolone use.Causality assessment using Naranjo scale proved majority of the ADRs to be probably due to the drugs, while only 8.13\%ADRs (table 1)were found to be possibly due to the drugs. Severity analysis using Hartwig scale showed majority of the patients had "mild" ADR (table \hyperref[tab_2]{1}). In this study females had a higher incidence of ADR as compared to the males. A higher incidence and more hospital admissions due to ADRs have been documented for women compared to men may be due to enhanced tissue sensitivity or the existence of sexrelated differences in pharmacokinetics.\par
Patients above 60 years of age are more likely to develop ADRs and may even need hospitalization due to them. This study also showed a higher incidence of ADRs in the geriatric population when compared to the adults and pediatric age groups due to their modified pharmacokinetic and pharmacodynamics properties.\par
The number of patients visiting the IPD and OPD were recorded in this study. The incidence of ADR was found to be more frequently reported in the OPD setting than the IPD setting of the hospital.ADRs are very common in patients prescribed with poly therapy. In this study too it was observed that as the number of drugs prescribed increased, the cases of ADRs had also increased.\par
NSAIDs were implicated in a majority of ADRs (26.6\%).Prednisolone was found to be the most offending drug followed by nimesulide and diclofenac. Previous Indian studies had documented non-opioid analgesics (18\%) and Aminoglicosides(48\%)(4).Mortality due to ADRs was 0.12\% of the total admissions. The one death observed in the study was relatedto nimesulide induced melaena.The most common organ system associated with ADRs was GIT system followed by cutaneous reactions. Some of the ADRs were preventable. For example, vancomycin injection caused finger necrosis due to a rapid injection. This ADR is avoidable by giving injection slowly. Some of the ADRs can be preventable by knowing clinical knowledge about drugs and their usage pattern. Elderly patients are at more risk of developing ADRs due to their modified pharmacokinetic and dynamic properties and renal dysfunction plays a major role in developing ADRs. Poly-pharmacy,age, comorbidity and no. of diagnosis were found to be risk factors for ADRs.\par
So clinical pharmacists should be uptodate about their clinical knowledge and attend daily ward rounds with the Nephrologists in the hospital as part of the clinical services. All health care professionals should be encouraged to report the suspected Adverse Drug Events (ADE's) and have actively monitored those ADR's to ensure safe pharmacotherapy. A regular follow up of patients on drugs is required for the early detection and prevention of ADRs to increase patient's compliance to drug therapy and to provide a better drug therapy by prevention of related morbidity and mortality.\begin{figure}[htbp]
\noindent\textbf{1}\includegraphics[]{image-2.png}
\caption{\label{fig_0}Figure 1 :}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{}\includegraphics[]{image-3.png}
\caption{\label{fig_1}}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{2} \par 
\begin{longtable}{P{0.85\textwidth}}
S.No\end{longtable} \par
 
\caption{\label{tab_0}Table 2 :}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{3} \par 
\begin{longtable}{P{0.013877551020408165\textwidth}P{0.10408163265306122\textwidth}P{0.06418367346938776\textwidth}P{0.09887755102040816\textwidth}P{0.04163265306122449\textwidth}P{0.09193877551020409\textwidth}P{0.1439795918367347\textwidth}P{0.2914285714285714\textwidth}}
S.\tabcellsep Variable\tabcellsep \tabcellsep \multicolumn{2}{l}{Total (n) Patients with}\tabcellsep Patients without\tabcellsep Prevalence of\tabcellsep OR *\\
No\tabcellsep \tabcellsep \tabcellsep \tabcellsep ADR\tabcellsep ADR\tabcellsep ADR\tabcellsep (95\% CI ** )\\
\tabcellsep \tabcellsep \tabcellsep 850\tabcellsep 72\tabcellsep 778\tabcellsep 8.47\%\tabcellsep \\
1\tabcellsep Age (yrs)\tabcellsep 0-18\tabcellsep 96\tabcellsep 9\tabcellsep 89\tabcellsep 9.37\%\tabcellsep 1 (reference)\\
\tabcellsep \tabcellsep 19-60\tabcellsep 714\tabcellsep 57\tabcellsep 657\tabcellsep 7.98\%\tabcellsep 0.85(0.41-1.8)\\
\tabcellsep \tabcellsep ? 60\tabcellsep 40\tabcellsep 6\tabcellsep 34\tabcellsep 15\%\tabcellsep 1.74(0.57-5.27)\\
2\tabcellsep Sex\tabcellsep Female\tabcellsep 360\tabcellsep 32\tabcellsep 328\tabcellsep 8.88\%\tabcellsep 1 (reference)\\
\tabcellsep \tabcellsep Male\tabcellsep 490\tabcellsep 40\tabcellsep 450\tabcellsep 8.16\%\tabcellsep 0.91(0.56-1.48)\\
3\tabcellsep Number of medications\tabcellsep ? 5\tabcellsep 200\tabcellsep 18\tabcellsep 182\tabcellsep 9\%\tabcellsep 1 (reference)\\
\tabcellsep \tabcellsep 6-10\tabcellsep 280\tabcellsep 19\tabcellsep 261\tabcellsep 6.77\%\tabcellsep 0.73(0.41-1.3)\\
\tabcellsep \tabcellsep ?11\tabcellsep 370\tabcellsep 35\tabcellsep 335\tabcellsep 9.45\%\tabcellsep 1.06(0.4-1.5)\\
4\tabcellsep Number of diagnosis\tabcellsep 1\tabcellsep 198\tabcellsep 9\tabcellsep 189\tabcellsep 4.54\%\tabcellsep 1 (reference)\\
\tabcellsep \tabcellsep 2\tabcellsep 300\tabcellsep 28\tabcellsep 272\tabcellsep 9.33\%\tabcellsep 2.16(0.99-4.61)\\
\tabcellsep \tabcellsep ?3\tabcellsep 352\tabcellsep 35\tabcellsep 317\tabcellsep 9.94\%\tabcellsep 2.31(1.1-4.9)\end{longtable} \par
 
\caption{\label{tab_1}Table 3 :}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{1} \par 
\begin{longtable}{P{0.31196808510638296\textwidth}P{0.2848404255319149\textwidth}P{0.13563829787234044\textwidth}P{0.1175531914893617\textwidth}}
\multicolumn{2}{l}{Assessment Criteria}\tabcellsep \multicolumn{2}{l}{No.of ADRs \% of ADRs}\\
Naranjo's\tabcellsep Possible(1-4)\tabcellsep 7\tabcellsep 8.13\\
Score\tabcellsep Probable(5-8)\tabcellsep 75\tabcellsep 87.2\\
(causality)\tabcellsep Highly probable(>9)\tabcellsep 4\tabcellsep 4.65\\
Hartwig\tabcellsep Mild\tabcellsep 44\tabcellsep 51.16\\
Criteria\tabcellsep Moderate\tabcellsep 38\tabcellsep 44.18\\
(severity)\tabcellsep Severe\tabcellsep 4\tabcellsep 4.65\end{longtable} \par
 
\caption{\label{tab_2}Table 1 :}\end{figure}
 			\footnote{© 2014 Global Journals Inc. (US)} 		 		\backmatter  			  				\begin{bibitemlist}{1}
\bibitem[Corsonello et al.]{b2}\label{b2} 	 		\textit{},  		 			A Corsonello 		,  		 			C Pedone 		,  		 			F Corica 		,  		 			C Mussi 		,  		 			P Carbonin 		,  		 			Antonelli Incalzi 		,  		 			R 		.  		 	 
\bibitem[ Gauhati Medical College]{b7}\label{b7} 	 		\textit{},  		 \url{http://gmchassam.gov.in/hospital.html}  	 	 		\textit{Gauhati Medical College}  		 	 
\bibitem[Walker and Whittlesea ()]{b5}\label{b5} 	 		\textit{},  		 			Roger Walker 		,  		 			Cate Whittlesea 		.  	 	 		\textit{Clinical Pharmacy and Therapeutics}  		2007. Churchill Livingstone. 4.  	 
\bibitem[Schumock et al. ()]{b10}\label{b10} 	 		‘A method for estimating the preventability of adverse drug reaction’.  		 			Thornton Schumock 		,  		 			U Busto 		,  		 			E M Sellers 		,  		 			P Sandor 		,  		 			I Ruiz 		,  		 			E A Roberts 		.  	 	 		\textit{Clin Pharmacolther}  		1992. 30  (2)  p. .  	 
\bibitem[Naranjo et al. ()]{b8}\label{b8} 	 		‘A method for estimating the probability of adverse drug reaction’.  		 			C A Naranjo 		,  		 			U Busto 		,  		 			E M Sellers 		,  		 			P Sandor 		,  		 			I Ruiz 		,  		 			E A Roberts 		.  	 	 		\textit{Clin Pharmacolther}  		1981. 30  (2)  p. .  	 
\bibitem[Hellden et al. ()]{b12}\label{b12} 	 		‘Adverse drug reactions and impaired renal function in elderly patients admitted to the emergency department: a retrospective study’.  		 			A Hellden 		,  		 			U Bergman 		,  		 			Von Euler 		,  		 			M Hentschke 		,  		 			M Odar-Cederlöf 		,  		 			I Ohlen 		,  		 			G 		.  	 	 		\textit{Drugs Aging}  		2009. 26  (7)  p. .  	 
\bibitem[Lisha Joshua, Padmini D Devi, Shoba Guido Pharmacovigilance Centre (ed.)]{b6}\label{b6} 	 		\textit{Adverse drug reactions in nephrology ward inpatients of a tertiary care hospital by},  		Lisha Joshua, Padmini D Devi, Shoba Guido Pharmacovigilance Centre (ed.)  		Bangalore, India.  		 			Department of Pharmacology, St. John's Medical College 		 	 
\bibitem[Concealed renal insufficiency and adverse drug reactions in elderly hospitalized patients]{b1}\label{b1} 	 		\textit{Concealed renal insufficiency and adverse drug reactions in elderly hospitalized patients},  		 	 
\bibitem[Gruppo Italiano di Farmacovigilanza nell'Anziano (GIFA)]{b3}\label{b3} 	 		\textit{Gruppo Italiano di Farmacovigilanza nell'Anziano (GIFA)},  		 	 
\bibitem[International drug monitoring: The role of national centers ()]{b0}\label{b0} 	 		\textit{International drug monitoring: The role of national centers},  		 series 498.  		1972. Geneva.  	 	 (Technical report) 	 (World health organization) 
\bibitem[Nazionale di Ricovero e Cura per Anziani]{b4}\label{b4} 	 		\textit{Nazionale di Ricovero e Cura per Anziani},  				 (Cosenza, Italy)  		 	 	 (andrea\textunderscore  corsonello@tin.it) 
\bibitem[Montastruc et al. ()]{b11}\label{b11} 	 		‘Pharmacovigilance for evaluating adverse drug reactions:value, organization, and methods’.  		 			J L Montastruc 		,  		 			A Sommeta 		,  		 			I Lacroixa 		,  		 			P Oliviera 		,  		 			G Durrieua 		,  		 			C Damase-Michela 		.  	 	 		\textit{Joint Bone Spine}  		2006. 73 p. .  	 
\bibitem[Hartwig et al. ()]{b9}\label{b9} 	 		‘Preventability and severity assessment in reporting adverse drug reactions’.  		 			S C Hartwig 		,  		 			J Siegel 		,  		 			P J Schneider 		.  	 	 		\textit{American journal of hospital pharmacy}  		1992. 49 p. .  	 
\end{bibitemlist}
 			 		 	 
\end{document}
